Evidence map›Paper›PMID 36538154›Full record

ArticleJournal of neurology2023

Language impairment in the genetic forms of behavioural variant frontotemporal dementia.

Kiran Samra, Amy M MacDougall, Arabella Bouzigues, Martina Bocchetta, David M Cash, Caroline V Greaves, Rhian S Convery, John C van Swieten, Harro Seelaar, Lize Jiskoot and 26 more

Full text read
In one paragraph

Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Kiran SamraDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.ORCID http://orcid.org/0000-0002-3105-7099
Amy M MacDougallDepartment of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Arabella BouziguesDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Martina BocchettaDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
David M CashDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Caroline V GreavesDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Rhian S ConveryDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
John C van SwietenDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
Harro SeelaarDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
Lize JiskootDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
Fermin MorenoCognitive Disorders Unit, Department of Neurology, Donostia Universitary Hospital, San Sebastian, Spain.
Raquel Sanchez-ValleAlzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
Robert LaforceClinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec, QC, Canada.
Caroline GraffDivision of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Bioclinicum, Karolinska Institutet, Solna, Sweden.
Mario MasellisSunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
James B RoweDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Barbara BorroniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Elizabeth FingerDepartment of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada.
Matthis SynofzikDepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
Daniela GalimbertiFondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Louvain, Belgium.
Alexandre de MendonçaLaboratory of Neurosciences, Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
Christopher R ButlerNuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.
Alexander GerhardDivision of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.
Simon DucharmeDepartment of Psychiatry, McGill University Health Centre, McGill University, Montreal, QC, Canada.
Isabelle Le BerSorbonne Université, Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, CNRS UMR 7225, AP-HP-Hôpital Pitié-Salpêtrière, Paris, France.
Pietro TiraboschiFondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Isabel SantanaUniversity Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Florence PasquierUniv Lille, Lille, France.
Johannes LevinDepartment of Neurology, Ludwig-Maximilians Universität München, Munich, Germany.
Markus OttoDepartment of Neurology, University of Ulm, Ulm, Germany.
Sandro SorbiDepartment of Neurofarba, University of Florence, Florence, Italy.
Jonathan D Rohrer *Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Lucy L Russell *Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK. l.russell@ucl.ac.uk.
Genetic FTD Initiative (GENFI)

Funding

Alzheimer Society (UK) AS-JF-19a-004-517Alzheimer's Research Trust ARUK-CRF2017B-2Association for Frontotemporal Dementias Research 2009CIHR 327387CIHR PJT-175242Deltaplan Dementie 733 051 042Deutsche Forschungsgemeinschaft EXC 2145 SyNergy - ID 390857198Diarophte Foundation 09-02-03-00European Reference Network for Rare Neurological Diseases 739510Fundació la Marató de TV3 20143810Instituto de Salud Carlos III PI20/00448JPND GENFI-PROX 2019-02248JPND Prefrontals 2015-02926JPND Prefrontals 2018-02754Mady Browaeys Fund for Research into Frontotemporal Dementia FTLDcMedical Research Council MC_U105597119Medical Research Council MC_UU_00005/12Medical Research Council MC_UU_00030/14Medical Research Council MR/K010395/1Medical Research Council MR/M008525/1Medical Research Council MR/M008983/1Medical Research Council MR/M023664/1Medical Research Council MR/P01271X/1Medical Research Council MR/T046015/1Medical Research Council SUAG/051 G101400National Brain Appeal RCN 290173National Institute for Health and Care Research BRC149/NS/MHNetherlands Organisation for Scientific Research HCMI 056-13-018Networks of Centres of Excellence of Canada MOP- 371851NIHR Cambridge Biomedical Research Centre BRC-1215-20014PrefrontALS, Italian Ministry of Health 733051042UK Dementia Research Institute SM-UCLO-MA-0519Wellcome Trust 103838
6 · The paper itself

Abstract

backgroundBehavioural variant fronto-temporal dementia (bvFTD) is characterised by a progressive change in personality in association with atrophy of the frontal and temporal lobes. Whilst language impairment has been described in people with bvFTD, little is currently known about the extent or type of linguistic difficulties that occur, particularly in the genetic forms.

methodsParticipants with genetic bvFTD along with healthy controls were recruited from the international multicentre Genetic FTD Initiative (GENFI). Linguistic symptoms were assessed using items from the Progressive Aphasia Severity Scale (PASS). Additionally, participants undertook the Boston Naming Test (BNT), modified Camel and Cactus Test (mCCT) and a category fluency test. Participants underwent a 3T volumetric T1-weighted MRI, with language network regional brain volumes measured and compared between the genetic groups and controls.

results76% of the genetic bvFTD cohort had impairment in at least one language symptom: 83% C9orf72, 80% MAPT and 56% GRN mutation carriers. All three genetic groups had significantly impaired functional communication, decreased fluency, and impaired sentence comprehension. C9orf72 mutation carriers also had significantly impaired articulation and word retrieval as well as dysgraphia whilst the MAPT mutation group also had impaired word retrieval and single word comprehension. All three groups had difficulties with naming, semantic knowledge and verbal fluency. Atrophy in key left perisylvian language regions differed between the groups, with generalised involvement in the C9orf72 group and more focal temporal and insula involvement in the other groups. Correlates of language symptoms and test scores also differed between the groups.

conclusionsLanguage deficits exist in a substantial proportion of people with familial bvFTD across all three genetic groups. Significant atrophy is seen in the dominant perisylvian language areas and correlates with language impairments within each of the genetic groups. Improved understanding of the language phenotype in the main genetic bvFTD subtypes will be helpful in future studies, particularly in clinical trials where accurate stratification and monitoring of disease progression is required.

Indexed as

Frontotemporal DementiaLanguage Development DisordersAtrophyC9orf72 ProteinHumansMagnetic Resonance ImagingMutationtau ProteinsC9orf72 Proteintau ProteinsC9orf72Frontotemporal dementiaGeneticsLanguageProgranulinTau

Identifiers

PMID36538154
PMCPMC10025186

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read43
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.